Netherlands Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1995
Buy Report Download FREE Resources

Published: November 02, 2022 Report Code: GDHC0069CHR-ST

Select Item

Netherlands Healthcare Market Overview

The Netherlands healthcare market comprises the pharmaceutical and medical devices market. The Netherlands pharmaceutical market size was $5.9 billion in 2021. In 2022, the Netherlands government invested $325 million in preclinical cancer treatment development. The government intends to promote the expansion of the Netherlands National Growth Fund to provide biotechnology with specific capabilities that will speed up the development of oncology prospects. The Netherlands pharmaceutical market offers great opportunities for pharmaceutical companies owing to the country’s enhanced investments in the R&D sector. The pharmaceutical market growth is attributed to the increased usage of medications for the treatment of chronic diseases due to the country’s aging demographics.

Netherlands Pharmaceutical Market Outlook 2021-2027 ($ Billion)
Netherlands Pharmaceutical Market Outlook 2021-2027 ($ Billion)Buy the Full Report for More Information on the Netherlands Pharmaceutical Market Forecast, Download a Free Report Sample

Market Size (2020) $5.9 billion
Key Segments ·       Generics

·       Biologics

·       Biosimilars

·       Over-the-Counter (OTC) Medicines
Key Import and Export Partners ·       Germany

·       The US

·       Belgium

·       Ireland

·       Italy

·       Spain
Leading Players ·       Sanofi

·       Pfizer

·       GlaxoSmithKline (GSK)

·       Novartis

·       Pharming Group NV
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

The Netherlands medical devices market was valued at $4.0 billion in 2021 and is expected to grow at a CAGR of more than 3% during 2022-2027. In 2021, the Netherlands developed a Personal Health Train platform that provides access to health data for researchers and innovators in the field of healthcare. It allows for limited data access while following privacy laws to promote patient participation. The Netherlands healthcare market research report is an essential source of information on the analysis of the healthcare, regulatory, and reimbursement landscape in the Netherlands. It identifies the key trends in the country’s pharmaceutical and medical devices market and provides insights into its demographic, regulatory, and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets.

Netherlands Medical Devices Market Outlook 2021-2027 ($ Billion)
Netherlands Medical Devices Market Outlook 2021-2027 ($ Billion)Buy the Full Report for More Insights on the Netherlands Medical Devices Market Forecast, Download a Free Report Sample

Market Size (2021) $4.0 billion
CAGR (2022-2027)  >3%
Key Segments ·       Hospital Supplies

·       Wound Care Management

·       Cardiovascular Devices

·       Orthopedic Devices

·       General Surgery Devices
Leading Players ·       Fresenius SE & Co.

·       Abbott

·       Siemens Healthineers

·       GE Healthcare

·       Qiagen
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Netherlands Pharmaceuticals Market Segmentation by Import and Export Partners

The key import and export partners of the Netherlands pharmaceuticals market are Germany, the US, Belgium, Ireland, and Switzerland among others. In 2021, Germany emerged as the leading import and export partner in the Netherlands pharmaceuticals market.

Netherlands Pharmaceuticals Market Analysis by Import and Export Partners, 2021 (%)
Netherlands Pharmaceuticals Market Analysis by Import and Export Partners, 2021 (%)Buy the Full Report for More Import and Export Partner Insights into the Netherlands Pharmaceuticals Market, Download a Free Report Sample

Netherlands Pharmaceuticals Market Segments

The key segments in the Netherlands pharmaceuticals market are generics, biologics, biosimilars, and over-the-counter (OTC) medicines.

Generics: The Dutch generic market has enormous potential for growth due to the high number of leading drugs going off-patent every year. The patent expiry of major products provides a good opportunity for generic manufacturers in the Netherlands. Actavis, Disphar International, Mylan, Pharmachemie, Apotex, and Sandoz are the major generics players in the Netherlands.

Netherlands Pharmaceutical Market Analysis by Segments
Netherlands Pharmaceutical Market Analysis by SegmentsBuy the Full Report for More Insights on the Key Segments in the Netherlands Pharmaceutical Market

Download a Free Sample Report

Netherlands Pharmaceuticals Market – Competitive Landscape

The leading players in the Netherlands pharmaceuticals market are:

  • Sanofi
  • Pfizer
  • GlaxoSmithKline (GSK)
  • Novartis
  • Pharming Group NV

Leading Netherlands Pharmaceuticals Market Players
Leading Netherlands Pharmaceuticals Market PlayersBuy the Full Report For More Insights on the Leading Netherlands Pharmaceuticals Market Players, Download a Free Report Sample

Netherlands Medical Devices Market Segments

The key segments in the Netherlands medical devices market are hospital supplies, wound care management, cardiovascular devices, orthopedic devices, general surgery devices, and others. In 2021, hospital supplies had the highest Netherlands medical devices market share.

Netherlands Medical Devices Market Analysis by Segments, 2021 (%)
Netherlands Medical Devices Market Analysis by Segments, 2021 (%)Buy the Full Report for more Segment Insights into the Netherlands Medical Devices Market, Download a Free Report Sample

Netherlands Medical Devices Market – Competitive Landscape

The major players in the medical devices market of the Netherlands are:

  • Fresenius SE & Co.
  • Abbott
  • Siemens Healthineers
  • GE Healthcare
  • Qiagen

In 2021, Fresenius SE & Co. had the highest share in the Netherlands devices market. Fresenius SE & Co. KGaA (Fresenius) is a global healthcare group that offers products and services for dialysis, hospitals, and outpatient treatment. It has major US, Germany, China, Sweden, and Japan manufacturing plants. The company has headquarters in Bad Homburg, Hessen, Germany, with its Netherlands office in Zeist.

Netherlands Medical Devices Market Analysis by Players, 2021 (%)
Netherlands Medical Devices Market Analysis by Players, 2021 (%)Buy the Full Report for More Insights in the Netherlands Medical Devices Market Players, Download a Free Report Sample

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving the Netherlands healthcare market.

  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the Netherlands healthcare market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership.

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the Netherlands Healthcare Market

2.3 Key Highlights: Healthcare Startups in the Netherlands

2.4 Key Events: The Netherlands Healthcare Timeline, 2016–22

2.5 Key Events: The Netherlands Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–22

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, the Netherlands, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, the Netherlands

3.5 Pharmaceutical Market – Market Segments

3.6 Pharmaceutical Market – Market Segments, Generics, the Netherlands

3.7 Pharmaceutical Market – Market Segments, Biologics and Biosimilars, the Netherlands

3.8 Pharmaceutical Market – Market Segments, OTC Medicines, the Netherlands

3.9 COVID-19 Epidemiology, the Netherlands

3.10 COVID-19 Impact and Developments in the Healthcare Market, the Netherlands

3.11 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Device Market – Major Segments

4.3 Medical Device Market – Hospital Supplies Market

4.4 Medical Device Market – Cardiovascular Devices Market

4.5 Medical Device Market – Orthopedic Devices Market

4.6 Medical Device Market – General Surgery Market

4.7 Medical Device Market – Wound Care Management Market

4.8 Medical Devices Market – Diagnostic Market

4.9 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, the Netherlands, 2021–22

6.2 Deal Analysis: Medical Device Market, the Netherlands, 2021–22

7. HealthTech Landscape

7.1 HealthTech Landscape, the Netherlands

7.2 HealthTech Deals Landscape, the Netherlands

7.3 Key HealthTech Deals, the Netherlands

7.4 Adoption of Technology in Healthcare, the Netherlands

7.5 Digital Statistics, the Netherlands

7.6 Regulatory Scenario Covering Use of Technology in Healthcare, the Netherlands

7.7 HealthTech Landscape: Benefits and Risks, the Netherlands

8. Market Access

8.1 Overview of Healthcare System, the Netherlands

8.2 Reimbursement Landscape, the Netherlands

8.3 Reimbursement Process, the Netherlands

8.4 Overview of Insurance Providers, the Netherlands

8.5 Healthcare Spending and Prescription Drug Price Trends, the Netherlands

8.6 Pricing Policies, the Netherlands

8.7 Market Access: Key Events Timeline, the Netherlands, 2010–21

8.8 Regulatory Landscape, the Netherlands

8.8.1 Marketing Authorization for Pharmaceutical Products, the Netherlands

8.8.2 Marketing Authorization for Pharmaceutical Products (Centralized Procedure), the Netherlands

8.8.3 Marketing Authorization for Pharmaceutical Products (Decentralized Procedure), the Netherlands

8.8.4 Marketing Authorization for Pharmaceutical Products (Mutual Recognition Procedure), the Netherlands

8.8.5 Marketing Authorization for Medical Devices, the Netherlands

8.8.6 Intellectual Property Rights, Patent, the Netherlands

8.8.7 Intellectual Property Rights, Trademark, the Netherlands

8.8.8 Clinical Trial Regulation Process, the Netherlands

8.8.9 Pharmaceutical Clinical Trials Landscape, the Netherlands

8.8.10 Medical Devices Clinical Trials Landscape, the Netherlands

8.8.11 Pharmaceutical Import and Export, the Netherlands

8.8.12 Pharmaceutical Advertising Regulations, the Netherlands

8.8.13 Pharmacy Regulations, the Netherlands

8.8.14 Labeling and Packaging Regulations, the Netherlands

9. Country Healthcare Landscape

9.1 The Netherlands Healthcare Policy Highlights

9.2 Healthcare Facilities, the Netherlands

9.3 Healthcare Resources, the Netherlands

9.4 Life Expectancy and Immunization Rate, the Netherlands

9.5 Environmental Health, the Netherlands

9.6 Healthcare Personnel, the Netherlands

9.7 Disease Burden, the Netherlands

9.8 Healthcare Expenditure, the Netherlands

10 Trade Associations, the Netherlands

11 Trade Fairs, the Netherlands

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Approved biosimilars, EU, 2021–22

Table 2: COVID-19 indicators (number of cases), global and the Netherlands, 2022

Table 3: COVID-19-related travel restrictions, the Netherlands, 2020–22

Table 4: Approved vaccines, the Netherlands, 2022

Table 5: COVID-19 vaccine trials, the Netherlands, 2022

Table 6: COVID-19 IVD products (October 2021 – October 2022), the Netherlands, 2021–22

Table 7: Medical devices market, major segments ($M), the Netherlands, 2021

Table 8: Hospital supplies market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021

Table 9: Cardiovascular devices market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021

Table 10: Orthopedic devices market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021

Table 11: General surgery devices market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021

Table 12: Wound care management market, the Netherlands, revenue ($M) and market share (%) of major companies, 2021

Table 13: Classification of medical devices, the Netherlands, 2022

Table 14: Trade fairs, the Netherlands, 2022

Figures

Figure 1: Pharmaceutical market, revenue ($B and €B), the Netherlands, 2015–21

Figure 2: Medical devices market, revenue ($B), the Netherlands, 2016–21

Figure 3: Healthcare start-ups in the Netherlands, 2022

Figure 4: Country profile, the Netherlands, 2021

Figure 5: Pharmaceutical market, revenue ($B and €B), the Netherlands, 2015–21

Figure 6: Pharmaceutical market, revenue forecast ($B and €B), the Netherlands, 2022–27

Figure 7: Pharmaceutical exports ($B), the Netherlands, 2014–21

Figure 8: Top export partners, the Netherlands, 2021

Figure 9: Pharmaceutical imports ($B), the Netherlands, 2014–21

Figure 10: Top import partners, the Netherlands, 2021

Figure 11: Pharmaceutical supply channel, the Netherlands, 2022

Figure 12: Members of BOGIN, the Netherlands, 2022

Figure 13: OTC market revenue ($B), the Netherlands, 2013–21

Figure 14: OTC market by sub-categories of drugs, revenue ($M), the Netherlands, 2021

Figure 15: COVID-19 cases, the Netherlands, 2020–22

Figure 16: COVID-19 deaths, the Netherlands, 2020–22

Figure 17: COVID-19 fiscal stimulus timeline, the Netherlands, 2020–21

Figure 18: COVID-19 stringency index (based on the share of people who are vaccinated), the Netherlands, 2020–22

Figure 19: COVID-19 containment and health index, the Netherlands, 2020–22

Figure 20: COVID-19 vaccine booster doses administration, number of vaccine doses administered per 100 people, the Netherlands, 2021–22

Figure 21: cumulative number of total vaccination doses administered, the Netherlands, 2021–22

Figure 22: top COVID-19 clinical trials sponsors by trial count, the Netherlands, 2021–22

Figure 23: COVID-19 clinical trials count by trial status, the Netherlands, 2021–22

Figure 24: Medical devices market, revenue ($b), the Netherlands, 2016–21

Figure 25: Medical devices market, revenue forecast ($B), the Netherlands,

2022–27

Figure 26: Medical devices market, major segments (%), the Netherlands, 2021

Figure 27: Hospital supplies market, revenue ($M), the Netherlands, 2017–27

Figure 28: Hospital supplies market, the Netherlands, market share of major players (%), 2021

Figure 29: Cardiovascular devices market, revenue ($M), the Netherlands, 2017–27

Figure 30: Cardiovascular devices market, the Netherlands, market share of major players (%), 2021

Figure 31: Orthopedic devices market, revenue ($M), the Netherlands, 2017–27

Figure 32: Orthopedic devices market, the Netherlands, market share of major players (%), 2021

Figure 33: General surgery devices market, revenue ($M), the Netherlands, 2017–27

Figure 34: General surgery devices market, the Netherlands, market share of major players (%), 2021

Figure 35: Wound care management market, revenue ($M), the Netherlands, 2017–27

Figure 36: Wound care management market, the Netherlands, market share of major players (%), 2021

Figure 37: Diagnostic market, revenue ($M), the Netherlands, 2017–21

Figure 38: Diagnostic market, revenue ($M), the Netherlands, 2022–27

Figure 39: Medical devices market, revenue ($B) of Major Companies, the Netherlands, 2021

Figure 40: Deal value and deal count, pharmaceutical market, the Netherlands, 2021–22

Figure 41: Deal value and deal count subtypes, pharmaceutical market, the Netherlands, 2021–22

Figure 42: Deal value and deal count, quarterly, pharmaceutical market, the Netherlands, 2021–22

Figure 43: Top therapy areas by deal value ($M), pharmaceutical market, the Netherlands, 2021–22

Figure 44: Top therapy areas by deal count, pharmaceutical market, the Netherlands, 2021–22

Figure 45: M&A deals by quarter, pharmaceutical market, the Netherlands, 2021–22

Figure 46: VC deals by quarter, pharmaceutical market, the Netherlands, 2021–22 (by value and by number)

Figure 47: Deal value and deal count, medical devices market, the Netherlands, 2021–22

Figure 48: Deal value and deal count subtypes, medical devices market, the Netherlands, 2021–22

Figure 49: Deal value and deal count, quarterly, medical devices market, the Netherlands, 2021–22

Figure 50: Top equipment sectors by deal value ($M), medical devices market,

the Netherlands, 2021–22

Figure 51: Top equipment sectors by deal count, medical devices market,

the Netherlands, 2021–22

Figure 52: M&A deals by quarter, medical devices market, the Netherlands,

2021–22 (by value and by number)

Figure 53: VC deals by quarter, medical devices market, the Netherlands,

2021–22 (by value and by number)

Figure 54: Dutch digitalization strategy, the Netherlands, 2021

Figure 55: Strategic pillars of the national strategy on AI, the Netherlands, 2019

Figure 56: Deal value ($M) and deal count, healthtech, the Netherlands, 2021–22

Figure 57: Deal value ($M) and deal count by sector, healthtech, the Netherlands, 2021–22

Figure 58: GDPR compliance checklist, EU, 2022

Figure 59: Organization of the health system, the Netherlands, 2022

Figure 60: Drug reimbursement process, the Netherlands, 2022

Figure 61: Public and private insurance coverage (% of total population), the Netherlands, 2013–2020

Figure 62: OOP expenditure (% of total expenditure on health), the Netherlands, 2013–20

Figure 63: Annual rate of change (%), consumer price index, the Netherlands, 2014–21

Figure 64: Organization of MEB, the Netherlands, 2022

Figure 65: Centralized procedure, the Netherlands, 2022

Figure 66: Decentralized procedure, the Netherlands, 2022

Figure 67: Mutual recognition procedure, the Netherlands, 2022

Figure 68: European patent approval process, the Netherlands, 2022

Figure 69: Pharmaceutical clinical trial count by trial status, the Netherlands, 2021–22

Figure 70: Pharmaceutical clinical trial count by indication, the Netherlands, 2021–22

Figure 71: Pharmaceutical clinical trial count by phase, the Netherlands, 2021–22

Figure 72: Top five pharmaceutical clinical trial sponsors by count, the Netherlands, 2021–22

Figure 73: Medical devices clinical trial count by trial status, the Netherlands, 2021–22

Figure 74: Medical devices clinical trial count by indication, the Netherlands, 2021–22

Figure 75: Medical devices clinical trial count by market categories, the Netherlands, 2021–22

Figure 76: Top five medical devices clinical trial sponsors by count, the Netherlands, 2021–22

Figure 77: Contents of the outer label of pharmaceutical products, the Netherlands, 2022

Figure 78: Number of hospitals, the Netherlands, 2013–21

Figure 79: Number of diagnostic units, the Netherlands, 2013–21

Figure 80: Hospital beds (per 1,000 population), the Netherlands, 2013–21

Figure 81: Acute care hospital beds (per 1,000 population), the Netherlands, 2013–21

Figure 82: Psychiatric care hospital beds (per 1,000 population), the Netherlands, 2013–21

Figure 83: Life expectancy at birth (years), the Netherlands, 2013–21

Figure 84: Immunization rate (%), the Netherlands, 2013–21

Figure 85: PM2.5 (µg per m3), the Netherlands, 2013–19

Figure 86: CO2 emissions (million tons), the Netherlands, 2013–20

Figure 87: Physicians (per 1,000 population), the Netherlands, 2013–21

Figure 88: Pharmacists (per 1,000 population), the Netherlands, 2013–21

Figure 89: Dentists (per 1,000 population), the Netherlands, 2013–21

Figure 90: Nurses (per 1,000 population), the Netherlands, 2013–21

Figure 91: Major causes of mortality (per 100,000 population), the Netherlands, 2019

Figure 92: Major causes of male mortality (per 100,000 population), the Netherlands, 2019

Figure 93: Major causes of female mortality (per 100,000 population), the Netherlands, 2019

Figure 94: DALYs by major disease (per 100,000 population), the Netherlands, 2019

Figure 95: Healthcare expenditure as percentage of GDP (%), the Netherlands, 2013-21

Figure 96: Health expenditure share (% of current health spending), the Netherlands, 2013-21

Figure 97: Pharmaceutical spending (% of total health spending), the Netherlands, 2013-21

Figure 98: Healthcare expenditure components by function (% of total health expenditure), the Netherlands, 2020

Frequently asked questions

Netherlands Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape standard reports
Currency USD
$1,995

Can be used by individual purchaser only

Most Popular
$2,992

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Netherlands Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Netherlands Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape in real time.

  • Access a live Netherlands Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more